Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium Selenite + Abiraterone in CRPC
NCT04296578Phase 1Withdrawn
- Sponsor
- Stanford University
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of sodium selenite in castration-resistant prostate cancer (CRPC), sponsored by Stanford University. Primary endpoint: Dose Limiting Toxicity at 2 weeks. Planned start Oct 2020; status: withdrawn.
02
Drugs
sodium selenite
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04296578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04296578.